DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Conditions: Ewing Sarcoma

First Posted Date: 2017-01-24

Last Posted Date: 2019-03-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03029481

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)

Not Applicable

Conditions: Stage IIIB Breast Cancer
Early-Stage Breast Carcinoma
Stage 0 Breast Cancer
Stage IIIC Breast Cancer
Cancer Survivor
Stage IA Breast Cancer
Stage IIIA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer

Interventions: Other: Educational Intervention
Other: Laboratory Biomarker Analysis
Procedure: Meditation Therapy
Other: Questionnaire Administration

First Posted Date: 2017-01-19

Last Posted Date: 2022-07-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 96

Registration Number: NCT03025139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2

Withdrawn

Conditions: Oligodendroglioma
Giant Cell Glioblastoma
Gliosarcoma
Small Cell Glioblastoma
Recurrent Glioblastoma

Interventions: Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2017-01-09

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03014804

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Phase 3

Completed

Conditions: Prostate Adenocarcinoma
Recurrent Prostate Carcinoma

Interventions: Radiation: Gallium Ga 68 Gozetotide
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2016-10-20

Last Posted Date: 2021-07-02

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1138

Registration Number: NCT02940262

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

Terminated

Conditions: B-Cell Non-Hodgkin Lymphoma
Absence of Signs or Symptoms
Digestive System Signs and Symptoms
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Indolent Adult Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Biospecimen Collection
Procedure: Colonoscopy
Procedure: Colposcopic Biopsy
Drug: Idelalisib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Procedure: Physical Examination
Procedure: Sigmoidoscopy

First Posted Date: 2016-10-10

Last Posted Date: 2021-07-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT02928510

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

Early Phase 1

Completed

Conditions: Autoimmune Disease
Crohn Disease
Rheumatoid Arthritis
Inflammatory Disorder
Systemic Lupus Erythematosus
Takayasu Arteritis

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Clofarabine
Procedure: Positron Emission Tomography

First Posted Date: 2016-10-05

Last Posted Date: 2020-09-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT02925351

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

Withdrawn

Conditions: Glioblastoma
Glioma

Interventions: Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-29

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02919332

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Not Applicable

Recruiting

Conditions: Glioblastoma

Interventions: Procedure: Computed Tomography
Radiation: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-16

Last Posted Date: 2024-11-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 50

Registration Number: NCT02902757

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Terminated

Conditions: Malignant Neoplasm

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Clofarabine
Procedure: Positron Emission Tomography

First Posted Date: 2016-09-05

Last Posted Date: 2020-08-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT02888301

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-08-26

Last Posted Date: 2021-07-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT02879994

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy